Arizona State Retirement System Has $54.17 Million Stock Holdings in Amgen Inc. $AMGN

Arizona State Retirement System increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,581 shares of the medical research company’s stock after purchasing an additional 2,047 shares during the period. Arizona State Retirement System’s holdings in Amgen were worth $54,166,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of AMGN. West Family Investments Inc. boosted its position in shares of Amgen by 1.7% during the 2nd quarter. West Family Investments Inc. now owns 1,833 shares of the medical research company’s stock valued at $664,000 after acquiring an additional 30 shares in the last quarter. Waverly Advisors LLC raised its position in Amgen by 1.3% in the second quarter. Waverly Advisors LLC now owns 41,925 shares of the medical research company’s stock worth $15,182,000 after purchasing an additional 539 shares in the last quarter. Empirical Finance LLC lifted its stake in Amgen by 3.4% during the second quarter. Empirical Finance LLC now owns 18,865 shares of the medical research company’s stock worth $6,831,000 after purchasing an additional 624 shares during the period. Nykredit A S acquired a new stake in Amgen during the second quarter valued at approximately $48,971,000. Finally, Parkside Financial Bank & Trust boosted its holdings in Amgen by 4.1% during the second quarter. Parkside Financial Bank & Trust now owns 4,153 shares of the medical research company’s stock valued at $1,504,000 after purchasing an additional 163 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of AMGN stock traded down $44.06 during trading hours on Tuesday, hitting $393.17. 6,824,446 shares of the company’s stock were exchanged, compared to its average volume of 2,713,826. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $447.03. The stock has a market cap of $212.56 billion, a price-to-earnings ratio of 24.44, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock’s 50-day moving average is $398.92 and its 200-day moving average is $367.59.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts forecast that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMGN. Oppenheimer increased their target price on Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Bank of America upped their price target on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. Robert W. Baird increased their price objective on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Finally, Mizuho boosted their target price on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research note on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $381.68.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported that IMDELLTRA (tarlatamab) combined with AstraZeneca’s Imfinzi significantly improved overall survival in a Phase 3 trial for first-line extensive-stage small-cell lung cancer. The study also met progression-free survival and objective response-rate endpoints, strengthening the commercial outlook for the oncology franchise. Amgen IMDELLTRA and IMFINZI Phase 3 results
• Positive Sentiment: William Blair maintained a Buy rating, citing the Phase 3 success for IMDELLTRA as support for Amgen’s growth prospects. UBS also said olpasiran could still demonstrate cardiovascular-risk reduction, although the evidence bar is now higher. William Blair maintains Buy rating on Amgen
• Neutral Sentiment: Cantor Fitzgerald reaffirmed its Neutral rating and set a $400 price target, indicating limited near-term upside based on the current valuation. Amgen analyst price target
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial reduced Lp(a) cholesterol but failed to lower cardiovascular events. The result undermined confidence in the broader Lp(a) drug class and raised concerns that Amgen’s 7,297-patient olpasiran study may face the same efficacy challenge. Because olpasiran is an important pipeline asset, investors reacted more strongly to the read-through than to Amgen’s favorable oncology update. Novartis cholesterol drug setback
• Negative Sentiment: BMO Capital Markets downgraded Amgen to Market Perform from Outperform, citing a more balanced risk-reward profile and limited near-term upside. Sector-wide selling and broader market pressure added to the decline. BMO downgrades Amgen

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.